MX2024011654A - Formulaciones que comprenden melfalan flufenamida y ciclodextrina - Google Patents

Formulaciones que comprenden melfalan flufenamida y ciclodextrina

Info

Publication number
MX2024011654A
MX2024011654A MX2024011654A MX2024011654A MX2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
flufenamide
formulations including
including melphalan
melphalan
Prior art date
Application number
MX2024011654A
Other languages
English (en)
Spanish (es)
Inventor
Fredrik Lehmann
Peter Teodorovic
Kristin Hammer
Rune Ringom
Original Assignee
Oncopeptides Innovation Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Innovation Ab filed Critical Oncopeptides Innovation Ab
Publication of MX2024011654A publication Critical patent/MX2024011654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024011654A 2022-03-24 2024-09-23 Formulaciones que comprenden melfalan flufenamida y ciclodextrina MX2024011654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (1)

Publication Number Publication Date
MX2024011654A true MX2024011654A (es) 2025-01-09

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011654A MX2024011654A (es) 2022-03-24 2024-09-23 Formulaciones que comprenden melfalan flufenamida y ciclodextrina

Country Status (11)

Country Link
US (1) US20250205155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499049A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510725A (cg-RX-API-DMAC7.html)
KR (1) KR20240161664A (cg-RX-API-DMAC7.html)
CN (1) CN119053323A (cg-RX-API-DMAC7.html)
AU (1) AU2023241241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202204171D0 (cg-RX-API-DMAC7.html)
IL (1) IL315551A (cg-RX-API-DMAC7.html)
MX (1) MX2024011654A (cg-RX-API-DMAC7.html)
WO (1) WO2023180565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
IL315551A (en) 2024-11-01
WO2023180565A1 (en) 2023-09-28
KR20240161664A (ko) 2024-11-12
AU2023241241A1 (en) 2024-10-31
CA3245985A1 (en) 2023-09-28
JP2025510725A (ja) 2025-04-15
CN119053323A (zh) 2024-11-29
GB202204171D0 (en) 2022-05-11
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
SA521422143B1 (ar) 15-pgdh مثبط
SA520420033B1 (ar) مركبات صيدلية
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112021021857A2 (pt) Métodos para formação de complexos de inclusão com derivados de beta-ciclodextrina hidrofílicos e composições dos mesmos
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
BRPI0509863A (pt) liberação de fármaco para fundo de olho
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
BR112023003106A2 (pt) Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112021011325A2 (pt) Derivados de rapamicina
BR112023019435A2 (pt) Inibidores de nek7
MX2021006969A (es) Ligante peptidico.
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
MX2020003993A (es) Derivados de bencimidazol y sus usos.
PE20250835A1 (es) Composiciones y uso de la tirzepatida
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
WO2023064612A3 (en) Pharmaceutical compositions for delivery of viral antigens and related methods
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana